

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Jill E. WOOD et al. : Box: PATENT APPLICATION
Serial No.: Div. of 09/083,399 : Group Art Unit: 1626
Filed: December 14, 2000 : Examiner: F. Higel
For: **RAF KINASE INHIBITORS**

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


Please amend the above-identified application as follows prior to calculation of the fees.












In the Claims:













Cancel claims 1 to 18 without prejudice or disclaimer.


Amend the claims as follows:

--19. A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae:












20. A method according to claim 19, comprising administering a compound of the formulae


















or


21. A method according to claim 19, comprising administering a compound of the formulae









22. A method according to claim 19, comprising administering a compound of the formula




23. A method according to claim 19, comprising administering a compound of the formula







24. A method according to claim 19, comprising administering a compound of formulae




25. A method according to claim 19, comprising administering a compound of formulae






























or







26. A compound of the formulae













or










27. A compound according to claim 26, of the formulae




or




28. A compound according to claim 26, of the formulae









29. A compound according to claim 26, of the formula




30. A compound according to claim 26, of the formula













31. A compound according to claim 26, of the formulae




or



32. A compound according to claim 26, of the formulae



or



REMARKS

The foregoing Amendment is presented in order to direct the claims of this divisional application to desired embodiments.

Respectfully submitted,

Harry B. Shubin (Reg. No. 32,004)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: (703) 812-5306
Internet Address: shubinh@mwzb.com

Filed: January 8, 2001

HBS/njr
K:\PAT\Bayer\1 D1\preliminary amendment.wpd